TY - JOUR
T1 - Clinical features, therapy patterns, outcomes and prognostic factors of solitary plasmacytomas
T2 - a report of the Israeli Myeloma Study Group
AU - Ganzel, Chezi
AU - Trestman, Svetlana
AU - Levi, Shai
AU - Gatt, Moshe E.
AU - Lavi, Noa
AU - Vaxman, Iuliana
AU - Rouvio, Ory
AU - Magen, Hila
AU - Lebel, Eyal
AU - Horowitz, Netanel A.
AU - Leiba, Merav
AU - Tadmor, Tamar
AU - Herzog Tzarfati, Katrin
AU - Surio, Celia
AU - Yeganeh, Shay
AU - Dally, Nagib
AU - Avivi, Irit
AU - Cohen, Yael C.
N1 - Publisher Copyright:
© 2022 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2022/12
Y1 - 2022/12
N2 - Solitary plasmacytoma (SP) is a rare plasma cell dyscrasia. In this retrospective multicenter study, 68 SP patients were included. Compared to solitary extramedullary plasmacytoma (SEP), patients with solitary bone plasmacytoma (SBP) were younger (57.3 vs. 70.9 years, p = 0.031), had larger plasmacytoma (median: 5.4 vs. 3 cm, p = 0.007) and higher median involved free light chain level (61 vs. 25.8 mg/L, p = 0.056). 92.6% of patients were treated by radiotherapy and 11.8% received systemic anti-myeloma treatment. With a median follow-up of 42 months, 45.6% of patients progressed (8.8%–recurrent SP, 36.8%–active myeloma). The median PFS was 58 months and the median OS has not been reached (10-year OS: 84.8%). Patients who received also anti-myeloma treatment had longer PFS compared to those who did not (median not reached vs. 48 months, p = 0.056). In conclusion, SBP and SEP appear to be different diseases. Radiotherapy is the cornerstone in the SP treatment. A large prospective trial is needed to evaluate the impact of adding systemic anti-myeloma treatment to local radiotherapy.
AB - Solitary plasmacytoma (SP) is a rare plasma cell dyscrasia. In this retrospective multicenter study, 68 SP patients were included. Compared to solitary extramedullary plasmacytoma (SEP), patients with solitary bone plasmacytoma (SBP) were younger (57.3 vs. 70.9 years, p = 0.031), had larger plasmacytoma (median: 5.4 vs. 3 cm, p = 0.007) and higher median involved free light chain level (61 vs. 25.8 mg/L, p = 0.056). 92.6% of patients were treated by radiotherapy and 11.8% received systemic anti-myeloma treatment. With a median follow-up of 42 months, 45.6% of patients progressed (8.8%–recurrent SP, 36.8%–active myeloma). The median PFS was 58 months and the median OS has not been reached (10-year OS: 84.8%). Patients who received also anti-myeloma treatment had longer PFS compared to those who did not (median not reached vs. 48 months, p = 0.056). In conclusion, SBP and SEP appear to be different diseases. Radiotherapy is the cornerstone in the SP treatment. A large prospective trial is needed to evaluate the impact of adding systemic anti-myeloma treatment to local radiotherapy.
KW - Solitary plasmacytoma
KW - multiple myeloma
KW - radiotherapy
KW - solitary bone plasmacytoma
KW - solitary extramedullary plasmacytoma
UR - http://www.scopus.com/inward/record.url?scp=85138302885&partnerID=8YFLogxK
U2 - 10.1080/10428194.2022.2118535
DO - 10.1080/10428194.2022.2118535
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 36075048
AN - SCOPUS:85138302885
SN - 1042-8194
VL - 63
SP - 3448
EP - 3455
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 14
ER -
